happened again urinary tract infection A “breakthrough” UK trial has found that an oral spray vaccine can prevent urinary tract infections for up to nine years.
Half of women and one in five men experience this painful bacterial infection, which is especially dangerous for older people. Symptoms include a burning sensation when urinating or needing to go to the bathroom more often than usual.
Recurrent infections occur in 20% to 30% of cases and require short-term antibiotic treatment. However, as antibiotic-resistant infections increase, these drugs are becoming less effective.
Clinicians at the Royal Berkshire Hospital in the UK conducted a long-term trial in which 89 patients were asked to spray the pineapple-flavored vaccine under their tongues every day for three months, and then followed the patients for nine years.
More than half (54%) of men and women with recurrent UTIs remained UTI-free nine years after vaccination, and no significant side effects were reported.
The average infection-free period for the cohort was 54.7 months (four and a half years) – 56.7 months for women and 44.3 months for men, one year less. Forty percent of trial participants reported receiving a second dose of the vaccine one or two years later.
Dr Bob Young, consultant urologist at Royal Berkshire NHS Foundation Trust, who co-led the study, said: “All of our participants had recurrent urinary tract infections before receiving the vaccine. For many women, these conditions can be difficult to treat.
“Nine years after first receiving this new urinary tract infection vaccine, about half of the participants remained infection-free.
“Overall, the vaccine is safe in the long term, and our participants reported fewer UTIs that were less severe. Many people with UTIs told us that simply drinking Plenty of water is enough to treat.
“Many participants told us that getting vaccinated restored their quality of life.”
The vaccine was developed by Spanish pharmaceutical company Immunotek. MV140 contains four types of bacteria in water. It is available for non-licensed use in 26 countries.
The research was presented this weekend at the European Association of Urology (EAU) Congress in Paris.
The new results are expected to be passed to the Medicines and Healthcare products Regulatory Agency (MHRA) before the vaccine can be passed on to the NHS for use.
Gernot Bonkat, chair of the EAU Urinary Infection Guidelines, said: “These findings are promising. Recurrent urinary tract infections are a huge economic burden, and overuse of antibiotic treatments may lead to antibiotic-resistant infections.”
“This follow-up study reveals encouraging data on the long-term safety and efficacy of the MV140 vaccine.
“While we need to be pragmatic, this vaccine is a potential breakthrough in preventing urinary tract infections and could provide a safe and effective alternative to traditional treatments.”
Follow us on Google news ,Twitter , and Join Whatsapp Group of thelocalreport.in
